[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Antidepressant reduces hospitalisations and deaths", "description": "Common antidepressant, $4 per course and it works\n\nEffect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial\nhttps://clinicaltrials.gov/ct2/show/NCT04727424\n\nhttps://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext\n\nhttps://www.togethertrial.com\n\nBackground\n\nPotential therapeutic role of fluvoxamine\n\nTOGETHER trial for acutely symptomatic patients\n\nTo assess the efficacy of fluvoxamine versus placebo\n\nIn preventing hospitalisation \n\nMethods\n\nPlacebo-controlled\n\nRandomised\n\nDouble blind\n\nAdaptive platform trial\n\n(Factoring in analyses at key points\n\nSo study design parameters like sample size, dosage, or patient selection can be adjusted accordingly)\n\nhttps://www.parexel.com/experience/adaptive-flexible-trials?KW=adaptive%20trial%20design&AG=%7Badgroup%7D&CS=MSS&utm_source=google&utm_medium=paid&utm_campaign=mss&utm_term=adaptive%20trial%20design&utm_content=106310559248&gclid=CjwKCAjw2vOLBhBPEiwAjEeK9t9AW3N8ysMeIkLgKabG5MRPEtJD9EJsq8hzBhnQ0ztDLPPUm5gppBoCe_oQAvD_BwE\n\nHigh-risk symptomatic Brazilian adults\n\nAge ranges and 58% female\n\nConfirmed positive for SARS-CoV-2\n\nWithin 7 days from first symptoms or diagnosis\n\nPatients from 11 clinical sites in Brazil\n\nPatients were randomly assigned (1:1)\n\nFluvoxamine (100 mg twice daily for 10 days), n = 741\n\nPlacebo, n = 756\n\nPrimary outcome\n\nHospitalisation, retention or transfer\n\nUp to 28 days post-random assignment\n\nFindings, Jan 20 to Aug 5, 2021\n\nThe proportion of patients observed in a COVID-19 emergency setting for more than 6 h\n\nOr transferred to a teritary hospital due to COVID-19 (87%)\n\nLower for the fluvoxamine group compared with placebo\n\nFluvoxamine group\n\n79 [11%] of 741\n\nPlacebo group\n\n119 [16%] of 756\n\nRelative risk 0\u00b768\n\n95% credible interval, 0\u00b752\u20130\u00b788\n\nProbability of superiority, 99\u00b78%\n\nFluvoxamine group\n\n17 deaths\n\nPlacebo group\n\n25 deaths\n\nOdds ratio [OR] 0\u00b768\n\n95% credible interval, 0\u00b736\u20131\u00b727\n\nNo significant differences in number of treatment emergent adverse events among patients in the fluvoxamine and placebo groups\n\nFluvoxamine group\n\n84 stopped taking\n\nPlacebo group\n\n64 \n\nThe absolute number of serious adverse events associated with fluvoxamine was lower than for placebo\n\nthis might reflect the modulatory effect of fluvoxamine on systemic inflammation\n\nMechanism?\n\nAnti-inflammatory\n\nPreventing cytokine storm\n\nAntiplatelet activity\n\nIncreasing plasma levels of melatonin\n\nIt is now crucial to establish whether a class effect exists?\n\nInteractions with vaccines, improved effect?\n\n stopped taking\n\nhttps://bnf.nice.org.uk/drug/fluvoxamine-maleate.html\n\n\nFor Adult \n\nInitially 50\u2013100\u202fmg daily", "link": "https://www.youtube.com/watch?v=qrYj5VJKLIs", "date_published": "2021-10-30 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Inconsistencies in official numbers", "description": "Is UK government data accurate? Or is there under-reporting?\n\nhttps://coronavirus.data.gov.uk\n\nhttps://covid.joinzoe.com/data#levels-over-time\n\nhttps://www.youtube.com/watch?v=Hc7A1bVuSJU\n\nhttps://covid.joinzoe.com/post/worryingly-close-to-100-000-new-cases-a-day\n\nPoor lateral flow test reporting\n\nLess than 50% have government \u2018classical symptoms\u2019\n\nTherefore, government under testing\n\nLoss of smell and taste, 6\n\nFever, 8\n\nONS\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsights\n\nOverall, coronavirus (COVID-19) infections continued to increase in England in the most recent week\n\nPercentage testing positive still highest in those in school years 7 to 11 \n\nOverall prevalence increases up to W/E 23rd October\n\n2.02% in England (1 in 50 people)\nWeek before, 1.79% (1 in 55 people) \n\n2.56% in Wales (1 in 40 people)\nWeek before, 2.31% (1 in 45 people)\n\n1.31% in Northern Ireland (1 in 75 people)\nWeek before, 0.76% (1 in 130 people)\n\n1.36% in Scotland (1 in 75 people)\nWeek before, 1.14% (1 in 90 people)\n\nCoronavirus antibodies remain high among UK adults (W/E 3rd October)\n\nhttps://blog.ons.gov.uk/2021/04/28/antibodies-and-immunity-how-do-they-relate-to-one-another/\n\n92.2% in England\n\n90.0% in Wales\n\n90.8% in Northern Ireland\n\n91.3% in Scotland\n\nPositivity has increased in younger adults\n\nShowing signs of a slow decline in older adults \n\nAntibody finger prick tests\n\nA negative antibody test does not mean that a person is not protected\n\nBuilding up to 150,000 UK antibody tests per month\n\nEvery month for the next year\n\nCoronavirus (COVID-19) deaths\nBetween 13 March 2020 and 1 October 2021, \n\n119,869 excess deaths above the five-year average\n\nGovernment figures\n\nhttps://coronavirus.data.gov.uk/details/deaths\n\n140,392\n\n163,515\n\nCurrent UK deaths (ONS)\n\n12,845 per week\n\n14.8% above average", "link": "https://www.youtube.com/watch?v=1Hfq9gBkwBE", "date_published": "2021-10-29 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]